What’s better: mammography screening or systemic treatment?
https://doi.org/10.18027/2224-5057-2014-4-3-9
Abstract
At least for the past 25 years, mammography screening has been the official policy of the healthcare systems of European countries, North America and Australia. Seven huge randomized trials have shown a reduction of mortality from breast cancer (BC) by 20-35% in women 50-61 years old, accepted the invitation to mammography screening. At the same time, some epidemiologists and other researchers in biostatistics doubt the success of mammographic screening, considering "suboptimal" randomization in some of these studies. Nordic Cochrane Centre also does not recommend this strategy to reduce mortality from breast cancer. There is no doubt that the progress of adjuvant systemic therapy (chemo-, endocrine and targeted therapy) has reduced mortality from breast cancer. Therefore, the contribution of screening and systemic therapy in reducing mortality from breast cancer has evolved in favor of therapy. Nevertheless, mammography screening still should be recommended, especially for women 50-69 years old. This strategy is confirmed by the recomendations of the European Union, ESMO (2014), and ASCO (2014).
About the Author
V. F. Semiglazov
НИИ онкологии им. Н. Н. Петрова, Санкт-Петербург
Russian Federation
Russian Federation
References
1. Gotzsche P., Jorgensen K. Screening for breast cancer with mammography (review). The Cochrane collaboration. The Cochrane library 2013, issne G., pp.1–17.
2. Miller A. B., Wall C., Baines CJ. Twenty five year follow up breast cancer incidence and mortality of the Canadian Breast Screening Study: Randomized Screening trial. BMJ.2014-vol 348-pp.366.
3. Kalager M,. Loberg M, Bretthauer M., Adami H. Comparative analysis of breast cancer mortality following mammography screening in Denmark and Norway. Ann Oncol., 2014-vol.25. — pp.1137–1143.
4. Bleyer A., Welch H. G. Effect of three decades of screening mammography on breast cancer incidence. N Eng J Med 2012. — vol. 367. — pp.1998–2005.
5. Baum M. Harms from breast cancer screening outweigh benefits if death caused by treatment included. BMJ 2013. Vol. —346. — pp 1385.
6. Irvin V., Kaplan R. Screening mammography and breast cancer mortality: meta — analysis of Quasi-experimental studies. Plos ONE. 2014. — vol. 9. — pp.105–115.
7. Toriola A. T., Colditz G.A, Trends in breast cancer incidence and mortality in the United Stales: implication for prevention. Breast cancer Res Trial. 2013. — vol 138-pp.665–673.
8. Sun E, Jena AB, Lakdawalle D, et al. The contributions of improved therapy and earlier detection to cancer survival gains 1988–2000. Forum Health Econ Policy, 2010. Vol 132.— pp.1195.
9. Early Breast Cancer Trialists Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet, 2005-Vol. — 365-pp.1687–1717.
10. Early Breast Cancer Trialists Collaborative Group, (Peto R, Davies C. et al): Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100.000 women in 123 randomised trials. Lancet, 2012 — Vol. — 379-pp.432–444.
11. Marmot MG., Altman DG., Cameron DA. et al. The benefits and harms of breast cancer screening: an independent review. Br J Cancer, 2013-vol. 108 (11). — pp.2205–2240.
12. Humphrey L. J., Helfand M., Chan BK et al. Breast cancer screening: a summary of the evidence for the US preventive Services Task Force. Ann Intern Med. 2012 — Vol. 137 (5). — pp. 347–360.
13. Tabar L., Duffy SW. Yen M. F., et al. All-cause mortality among breast cancer patients in a screening trial: support for breast cancer mortality as an end point. J Med Screen.2002-Vol.9 — pp.159–162.
14. Morris E. Rethinking breast cancer screening: ultra fast breast magnetic resonance imaging. J Clin Oncol. 2014-Vol. — 32.pp. —2281–2283.
15. Tabar L., Vita K. B., Chen TH et. al. Swedish two-county trial: impact of mammography screening on breast cancer mortality during 3 decades. Radiology, 2011. — Vol.260 — pp. 658–663.
16. Kopans D. B. Arguments against mammography screening continue to be based on faulty science. Oncologist, 2014. — Vol.17-pp.107–112.
17. Morris EA: Diagnostic breast MR imaging: Current status and future directions. Magn Reson Imaging Clin n Am, 2010, Vol. — 18:57:-74.
18. Kuhl CL, Schrading S, Strobel K, et al: Abbreviated breast magnetic resonance imaging (MRI): First postcontrast subtracted images and maximum-intensity projection — A novel approach to breast screening with MRI. J Clin Oncol, 2014. Vol. — 32 pp. 2304–2310.
19. Saadatmand S. Tilanus-Linthorst MM, Rutgers EJ. Et. Al: Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging. J Natl Cancer Inst., 2013 vol. — 105 pp.1314–1321.
20. Burton R., Bell R. The global challenge of reducing breast cancer mortality. The Oncologist, 2013 Vol. — 18. — pp. 1200–1202.
21. Mittra L., Mishra G. A., Singh S. et al. A cluster randomised, controlled trial of breast and cervix cancer screening in Mumbai, India. Int J Cancer, 2010. — Vol. 126. — pp. 926–984.
Review
For citations:
Semiglazov V.F. What’s better: mammography screening or systemic treatment? Malignant tumours. 2014;(4):3-9. (In Russ.) https://doi.org/10.18027/2224-5057-2014-4-3-9
Views:
1103
Email this article 